211 related articles for article (PubMed ID: 20616905)
1. Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.
Di Costanzo F; Gasperoni S; Rotella V; Di Costanzo F
Onco Targets Ther; 2009 Feb; 2():179-88. PubMed ID: 20616905
[TBL] [Abstract][Full Text] [Related]
2. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Henderson IC; Bhatia V
Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
[TBL] [Abstract][Full Text] [Related]
3. First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.
Gupta N; Hatoum H; Dy GK
Int J Nanomedicine; 2014; 9():209-21. PubMed ID: 24399877
[TBL] [Abstract][Full Text] [Related]
4. Albumin-bound paclitaxel: a next-generation taxane.
Gradishar WJ
Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
[TBL] [Abstract][Full Text] [Related]
5. Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers-Improvements in Clinical Efficacy and Safety.
Hassan MS; Awasthi N; Ponna S; von Holzen U
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509639
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.
Vishnu P; Roy V
Breast Cancer (Auckl); 2011; 5():53-65. PubMed ID: 21603258
[TBL] [Abstract][Full Text] [Related]
7. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
Vishnu P; Roy V
Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
[TBL] [Abstract][Full Text] [Related]
8. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer.
Al-Hajeili M; Azmi AS; Choi M
Onco Targets Ther; 2014; 7():187-92. PubMed ID: 24523592
[TBL] [Abstract][Full Text] [Related]
9. nab-Paclitaxel mechanisms of action and delivery.
Yardley DA
J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
[TBL] [Abstract][Full Text] [Related]
10. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy evaluation of albumin-bound paclitaxel.
Cecco S; Aliberti M; Baldo P; Giacomin E; Leone R
Expert Opin Drug Saf; 2014 Apr; 13(4):511-20. PubMed ID: 24559090
[TBL] [Abstract][Full Text] [Related]
12. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective.
Dranitsaris G; Yu B; King J; Kaura S; Zhang A
Clinicoecon Outcomes Res; 2015; 7():249-56. PubMed ID: 25999749
[TBL] [Abstract][Full Text] [Related]
14. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
Chirgwin J; Chua SL
Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
[TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval.
Yamamoto Y; Kawano I; Iwase H
Onco Targets Ther; 2011; 4():123-36. PubMed ID: 21792318
[TBL] [Abstract][Full Text] [Related]
16. Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies.
Loong HH; Chan AC; Wong AC
J Cancer; 2016; 7(3):268-75. PubMed ID: 26918039
[TBL] [Abstract][Full Text] [Related]
17. Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ; Soon-Shiong P; Desai N
Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
[TBL] [Abstract][Full Text] [Related]
18. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
[TBL] [Abstract][Full Text] [Related]
19. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
Megerdichian C; Olimpiadi Y; Hurvitz SA
Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
[TBL] [Abstract][Full Text] [Related]
20. Albumin-bound Paclitaxel: in metastatic breast cancer.
Robinson DM; Keating GM
Drugs; 2006; 66(7):941-8. PubMed ID: 16740010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
